The revised MCID value of 1.1% to 1.5% for safe acute ischemic stroke treatments can guide future clinical trial design and regulatory decisions.
Answers are grounded in this paper and cite their sources.
Revised MCID may refine stroke trial sample sizes; leaves open prospective validation before regulatory adoption.
Stroke expert responses to MCID surveys are affected by anchoring and centrality bias. When survey design takes these into account, the expert-derived MCID for a safe acute ischemic stroke treatment is 1.1% to 1.5%, in accord with actual physician behavior in guideline writing and clinical practice. This revised MCID value can guide clinical trial design and grant-funding and regulatory agency decisions.
No takes yet. Share an insight, caveat, or question.
Cranston et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: